Oruka Therapeutics (ORKA) General Counsel T Sells $936K of Stock

Quinlan Paul T, the General Counsel of Oruka Therapeutics, Inc. (NasdaqGM: ORKA), sold 10,000 shares on September 21, 2026, for approximately $936,417. This planned transaction came as the stock continues to show strong performance in the biotechnology sector.

Inside Quinlan Paul T's Trade

Paul's sale of 10,000 shares was executed at an average price of $93.64. This move reflects a significant reduction in his holdings, as he manages his stake in the company ahead of upcoming developments. With this sale, his remaining holdings are not disclosed, but the transaction highlights his role as a key executive in the company.

Other Institutional Activity in Oruka Therapeutics

Several other institutional investors have also made moves in Oruka Therapeutics. FMR, LLC increased its stake by 1,626,036 shares, bringing its total to 9,057,645 shares worth about $655.9 million. Blackrock Inc. added 1,463,053 shares, resulting in a total of 4,990,181 shares valued at approximately $361.4 million. Meanwhile, Capital World Investors grew its holdings by 1,700,820 shares, reaching 3,401,639 shares worth about $246.3 million.

Oruka Therapeutics, Inc. Stock Down 1.3%

Oruka Therapeutics' shares have been trading near their 52-week high of $115.52, indicating strong market interest. The stock closed at $94.96 on the last trading day, near its moving average of $96.42. The current market cap stands at approximately $6.18 billion, reflecting its position in the healthcare sector focused on innovative biopharmaceuticals.

Recent Earnings

Oruka Therapeutics is scheduled to report its next earnings on November 11, 2026. The company currently faces a challenging profitability landscape, with a reported EPS of -$2.04 and a net margin of 0.0%. Investors are likely anticipating updates on its clinical trials and product pipeline during the upcoming earnings call.

Insider Buying and Selling at Oruka Therapeutics, Inc.

In addition to Paul T's sale, other insiders have also been active. Chief Medical Officer Joana Goncalves sold 7,000 shares at an average price of $74.81 on October 15, 2026, valued at approximately $523,647. Senior Vice President of Finance Arjun Agarwal purchased 9,459 shares on June 12, 2026, for about $150,175, showing some level of insider investment.

Analysts Set New Price Targets

On September 24, 2026, Wedbush reiterated its Outperform rating on Oruka Therapeutics with a price target of $165. HC Wainwright & Co. also reiterated its Buy rating with a target of $120. The consensus among analysts is a strong buy, with a mean price target of $155 based on 12 opinions.

About Oruka Therapeutics

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, CA. It specializes in developing novel monoclonal antibody therapies for conditions like psoriasis and other inflammatory diseases. The company's lead products are currently in phase 2 trials, aiming to address significant medical needs in the field of immunology.

Bottom Line

As Oruka Therapeutics approaches its next earnings report on November 11, 2026, investors will be watching closely for updates from the company. The recent insider transactions and strong analyst ratings suggest a dynamic environment as the company progresses in its clinical trials. Keep in mind that the insider trade reflects past positions and may not represent current holdings.